Skip to main content
Top
Published in: Medical Oncology 4/2010

01-12-2010 | Original Paper

Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics

Authors: Yandong Nan, Faguang Jin, Shuanying Yang, Yingxuan Tian, Yonghong Xie, Enqing Fu, Hong Yu

Published in: Medical Oncology | Issue 4/2010

Login to get access

Abstract

Carcinogenesis of lung adenocarcinoma remains unclear and very few biomarkers have been accepted for routine clinical use. In order to explore the pathogenesis and screen ideal biomarkers, we conducted cell-map proteomics study in human lung adenocarcinoma. Homogeneous lung adenocarcinoma cells were purified by laser capture microdissection (LCM). A high performance liquid chromatography (HPLC) system was used to separate the total solution proteins. The resulting MS/MS spectra were automatically searched for proteins against IPI human protein database using the TurboSEQUEST searching engine. Physico-chemical properties of the identified proteins, including molecular weight (MW), isoelectric point (PI), were described based on various proteomics web server and statistical analysis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were used to analyze function of expressed proteins and screen candidate biomarkers according to biological annotation. A total of 843 distinct proteins were identified and were categorized as 10 sorts of molecular function and 17 sorts of biological process based on GO annotation. Further searching against KEGG pathways found that six proteins were involved in WNT signaling pathway, apoptosis pathway, Erb-2 signaling pathway, p53 signaling pathway, ubiquitin-mediated proteolysis and were might be hopefully screened as candidate markers of lung adenocarcinoma. The present study through LCM and cell-map proteomics showed a full view on the expressed protein profiles of lung adenocarcinoma. Several candidate markers are hopeful to be used as molecular targets of diagnosis, treatment and prognosis of lung adenocarcinoma.
Literature
2.
go back to reference Raponi M, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66:7466–72.CrossRefPubMed Raponi M, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66:7466–72.CrossRefPubMed
3.
4.
go back to reference Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61:7908–12.PubMed Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61:7908–12.PubMed
5.
go back to reference Garber ME, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784–9.CrossRefPubMed Garber ME, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784–9.CrossRefPubMed
6.
go back to reference Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis. 2000;21:1210–7.CrossRefPubMed Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis. 2000;21:1210–7.CrossRefPubMed
7.
go back to reference He P, et al. The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics. 2005;5:3442–53.CrossRefPubMed He P, et al. The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics. 2005;5:3442–53.CrossRefPubMed
8.
go back to reference Li C, et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics. 2004;3:399–409.CrossRefPubMed Li C, et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics. 2004;3:399–409.CrossRefPubMed
9.
go back to reference Baker H, et al. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol. 2005;41:183–99.CrossRefPubMed Baker H, et al. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol. 2005;41:183–99.CrossRefPubMed
10.
go back to reference Kremer A, Schneider R, Terstappen GC. A bioinformatics perspective on proteomics: data storage, analysis, and integration. Biosci Rep. 2005;25:95–106.CrossRefPubMed Kremer A, Schneider R, Terstappen GC. A bioinformatics perspective on proteomics: data storage, analysis, and integration. Biosci Rep. 2005;25:95–106.CrossRefPubMed
11.
go back to reference Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. Pathol. 2008;214:283–93.CrossRef Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. Pathol. 2008;214:283–93.CrossRef
12.
go back to reference Golubovskaya VM, Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol. 2007;263:103–53.CrossRefPubMed Golubovskaya VM, Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol. 2007;263:103–53.CrossRefPubMed
13.
go back to reference Wiley SR, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–46.CrossRefPubMed Wiley SR, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–46.CrossRefPubMed
14.
go back to reference Nakayama M, et al. Fibroblast growth factor-Inducible 14 mediates multiple pathways of TWEAK-Induced cell death. J Immunol. 2003;170:341–8.PubMed Nakayama M, et al. Fibroblast growth factor-Inducible 14 mediates multiple pathways of TWEAK-Induced cell death. J Immunol. 2003;170:341–8.PubMed
15.
go back to reference Ribe A, McNutt NS. S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol. 2003;16:505–11.CrossRefPubMed Ribe A, McNutt NS. S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol. 2003;16:505–11.CrossRefPubMed
16.
go back to reference Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res. 2004;10:7775–84.CrossRefPubMed Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res. 2004;10:7775–84.CrossRefPubMed
17.
go back to reference Funasaka T, Hu H, Yanagawa T, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res. 2007;67:4236–43.CrossRefPubMed Funasaka T, Hu H, Yanagawa T, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res. 2007;67:4236–43.CrossRefPubMed
18.
go back to reference Falini B, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92:519–32.CrossRefPubMed Falini B, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92:519–32.CrossRefPubMed
19.
go back to reference Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98:201–13.CrossRefPubMed Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98:201–13.CrossRefPubMed
20.
go back to reference Quan C, et al. Enhanced expression of peroxiredoxin VI and I correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.CrossRefPubMed Quan C, et al. Enhanced expression of peroxiredoxin VI and I correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.CrossRefPubMed
21.
go back to reference Reddy RK, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915–24.CrossRefPubMed Reddy RK, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915–24.CrossRefPubMed
22.
go back to reference Xing X, Lai M, Wang Y, Xu E, Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta. 2006;364:308–15.CrossRefPubMed Xing X, Lai M, Wang Y, Xu E, Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta. 2006;364:308–15.CrossRefPubMed
Metadata
Title
Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics
Authors
Yandong Nan
Faguang Jin
Shuanying Yang
Yingxuan Tian
Yonghong Xie
Enqing Fu
Hong Yu
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9393-7

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.